| Vol. 11.03 – 26 January, 2022 |
| |
|
|
| The isolated cells were characterized for cancer stem cell characteristics in vitro and in vivo as well as their responses to anticancer drugs. [Journal of Experimental & Clinical Cancer Research] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that the low expression of RICH1 in breast cancer was associated with poor prognosis. Depletion of RICH1 promoted the stemness and disrupted the normal epithelial architecture of MCF10A cells. [Cell Death & Disease] |
|
|
|
| Researchers demonstrated that significant upregulation of ATAD2 and SMARCA4, and downregulation of SMARCA2 was consistently associated with enriched CSC-like phenotype, respectively. [International Journal of Cancer] |
|
|
|
| Keratin 13 (KRT13) plays an important role in breast cancer progression and metastasis. The authors elucidated the mechanism by which KRTs promoted breast cancer growth and metastasis. [Breast Cancer Research] |
|
|
|
| Scientists found estrogen receptor beta could increase the CSC population via altering the circPHACTR4/miR-34b-5p/c-Myc signaling. [FASEB Journal] |
|
|
|
| Four types of human oral squamous carcinoma cell lines, non-radioresistant cell lines, and radioresistant cell lines, were used to measure the surviving fraction after single-dose irradiation, split-dose irradiation, and multi-fractionated irradiation. [Scientific Reports] |
|
|
|
| In vitro mammary spheroid formation, flow cytometry assay on CD24−/CD44+ sub-population, ALDH activity detection, cell viability assay and western blot analysis, and in vivo tumor-initiating analysis were performed to examine the effects of Tanshinone IIA on the stemness of breast cancer cells. [Experimental Hematology & Oncology] |
|
|
|
| Downregulation of SET-domain containing 5 (SETD5) significantly decreased breast cancer stem-like cells properties and glycolysis in vitro and in vivo. [American Journal of Pathology] |
|
|
|
| Researchers used Kaempferol in combination with Verapamil, in multiple assays to determine if there was an inhibitory effect on breast CSCs. [Toxicology and Applied Pharmacology] |
|
|
|
| The expressions and interactions of GDF-15, FOXM1, and stemness (OCT4 and SOX2), and drug resistance (ABCC5) markers were evaluated in breast cancer. [Molecular Biology Reports] |
| |
|
|
|
| Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-like phenotype characterized by uncontrolled growth. Polycomb Group proteins are members of multiprotein complexes that are highly conserved throughout evolution. [Cell Research] |
|
|
|
|
| Lyell Immunopharma, Inc. announced that US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK. [Lyell Immunopharma, Inc. (Globenewswire, Inc.)] |
|
|
|
| OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients. [OSE Immunotherapeutics SA] |
|
|
|
|
|
|
|
| Moffit Cancer Center – Tampa Bay, Florida, United States |
|
|
|
| Luxembourg Institute of Health – Luxembourg, Luxembourg |
|
|
|
| Wayne State University School of Medicine – Detroit, Michigan, United States |
|
|
|
| Queen Mary University of London – London, England, United Kingdom |
|
|
|
| Queen Mary University of London – London, England, United Kingdom |
|
|
|
|